NCT02945319View on ClinicalTrials.gov

Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma

CompletedOBSERVATIONAL

Enrollment

373

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Splenic Marginal Zone Lymphoma

Trial Locations (1)

6500

IOSI, Bellinzona

All Listed Sponsors

lead

International Extranodal Lymphoma Study Group (IELSG)

OTHER

NCT02945319 - Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma | Biotech Hunter | Biotech Hunter